Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the “Agreement”) with Core One Labs Inc. (CSE: COOL) (“Core One Labs”) to pursue the formation of a joint venture involving the development, regulatory approval and marketing of biosynthetic psilocybin and other psychedelic compounds (the “Joint Venture”).

“Lobe is pleased to pursue a partnership with Core One Labs, as we continue our business expansion efforts within the rapidly growing psilocybin and psychedelics space,” said Philip Young, CEO of Lobe. “A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.”


The Agreement proposes that Core One Labs would develop and manage the cGMP production and delivery of biosynthetic psilocybin and Lobe would be responsible for the clinical development, and commercialization of the product(s). Vocan Biotechnologies Inc. (“Vocan“), a wholly-owned subsidiary of Core One Labs, would produce the biosynthetic psilocybin and other psychedelic compounds to be used. Vocan has identified a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms.

The structure and terms of the Joint Venture remains subject to negotiation between the parties. The Joint Venture is subject to a number of other conditions, including but not limited to, legal and regulatory due diligence by the parties, negotiation and execution of a definitive agreement (the “Definitive Agreement“) with binding terms and conditions for the Joint Venture, including, but not limited to, customary representations and warranties, royalty structure for payments by Core One Labs for product sales initiated by Lobe, the price of biosynthetic psilocybin to Lobe, the production schedule of Core One Labs and the timeframe for product order fulfillment and delivery, which shall supersede the Agreement and receipt of applicable corporate and regulatory approvals. There can be no assurance that the Joint Venture will be completed as proposed herein or at all.

About Lobe Sciences Ltd.

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the proposed Joint Venture with Core One Labs and products expected to be developed, approved and commercialized, statements regarding research and development using psychedelic compounds, the development of innovative devices and delivery mechanisms to improve mental health and wellness, the initiation of future clinical trials, and business expansion initiatives, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including that the expected benefits to be derived from the proposed joint venture with Core One Labs may not materialize as expected, including that the Joint Venture may be unsuccessful in developing, obtaining regulatory approval and commercializing any products and/or the risk that the Company may not realize a return on its investment in the Joint Venture, changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; the completion of a Definitive Agreement, that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82040

News Provided by Newsfile via QuoteMedia

Juan Monteverde founder and managing partner at Monteverde & Associates PC a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City is investigating Harvest Health & Recreation, Inc. (“HRVSF” or the “Company”) ( HRVSF ) relating to its proposed acquisition by Trulieve Cannabis Corp. Under the terms of the agreement, HRVSF shareholders will receive 0.1170 shares of Truelieve per share they own.

The investigation focuses on whether Harvest Health & Recreation, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced that the Company will be participating at the BMO Capital Markets 16 th Annual Farm to Market Virtual Conference. Chief Executive Officer, Miguel Martin and Chief Financial Officer, Glen Ibbott will be conducting virtual one-on-one meetings with investors throughout the day on Wednesday, May 19 and Thursday, May 20, 2021 .

Keep reading... Show less

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) and Matica subsidiary, West Island Culture Inc. (“West Island”) are pleased to introduce our newest cannabis brand to the market CITOYENTM . CITOYENTMis a more accessible brand of quality cannabis to come out of Montreal’s West Island, The People’s Flower.

All CITOYENTM flower products are craft grown, quality cannabis offerings at lower entry prices and with greater volumes in comparison to our premium OuestTM products. There are currently two product families in the CITOYENTMbrand. CITOYENTMGold Star products are high THC craft products. The CITOYENTM Red Star craft products have a mid to high THC range. Both sets of products still offer the strong bag appeal found with the QuestTM brand stemming from our focus on rich terpene profiles and attractive visual attributes. The CITOYENTM brand strives to provide a greater number consumers with a taste of what a high quality bud in the legal market should be.

Keep reading... Show less

Two US-based multi-state operators (MSOs) added fuel to the ongoing merger and acquisition (M&A) train currently making its way across the cannabis sector.

On the flip side, one of Canada’s biggest cannabis producers told the market this week that it has no interest in further acquisitions in the Canadian market.

Keep reading... Show less

 Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”), a wellness company that makes and sells plant-based products, is ramping up production at its Victoria, BC production facility to fulfill incoming orders from seven Whole Foods Market in Ontario, Canada (“Whole Foods”).

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/84022_947985ee845d7afb_001.jpg

Keep reading... Show less